The Evolving Role of CDK4/6 Inhibitors in Early and Recurrent Breast Cancer: Clinical and Translational Findings and Work in Progress
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 December 2026 | Viewed by 591
Editor
Interests: breast cancer; de-escalation strategies; intraoperative radiotherapy; neoadjuvant therapy; immune therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have fundamentally transformed the therapeutic landscape for hormone receptor-positive, HER2-negative breast cancer, establishing a new standard of care in both advanced and high-risk early-stage disease when combined with endocrine therapy. The clinical success of agents such as palbociclib, ribociclib, and abemaciclib is underpinned by their ability to arrest cell cycle progression at the G1/S checkpoint, resulting in significant improvements in progression-free and overall survival for select patient populations. Beyond their cytostatic effects, recent research has revealed that CDK4/6 inhibition exerts broader biological impacts—including modulation of tumor metabolism—induction of cellular senescence, and enhancement of antitumor immunity, thereby opening new avenues for combination strategies and expanding their potential utility across diverse malignancies.
Despite these advances, several challenges remain, including the emergence of acquired resistance, identification of predictive biomarkers, and the optimization of treatment sequencing and combination regimens. Ongoing translational and clinical research is focused on elucidating mechanisms of resistance, refining patient selection, and exploring novel therapeutic combinations to maximize clinical benefit. This Special Issue aims to provide a comprehensive overview of the current state of clinical and translational CDK4/6 inhibitor research in both the early and metastatic settings, highlight recent mechanistic insights, and discuss future directions for clinical application and drug development in oncology.
Prof. Dr. Hans-Christian Kolberg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CDK4/6 inhibitors
- breast cancer
- treatment resistance
- combination therapy
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
